Myths & Urban Legends in Drug Development: Lessons Learned for Small Biotech Companies

April 4, 2020

Drs. Michelle Higgin and Lisa Lallos talk to hundreds of newly formed biotech companies every year and have the opportunity to hear their creative strategies for building value on extremely lean budgets. Many of those ideas are ground breaking, but some are based on misconceptions that lead to costly delays and missed investment opportunities. Knowing how to side step these landmines will help streamline the development path but also offer some new strategies. During the presentation, they share some truths, myths and legends spanning drug development–preclinical, CMC, clinical, regulatory and program management. This video series will help early biotech companies avoid these potential pitfalls while providing alternatives paths to IND and clinical studies.

Select a video from the collection below:

Myths and Urban Legends in Drug Development Part I: Introduction

Myths and Urban Legends in Drug Development Part I: Introduction

Myths and Urban Legends in Drug Development Part II: Pre Clinical Myths

Myths and Urban Legends in Drug Development Part III: CMC Myths

Myths and Urban Legends in Drug Development Part IV: Regulatory Myths

Myths and Urban Legends in Drug Development Part V: Clinical Myths

Myths and Urban Legends in Drug Development Part VI: Project Management Myths